Critical Path Institute’s New Business Model: An Interview With CEO Compton
Executive Summary
After six months on the job, Carolyn Compton, the institute’s new chief executive, has overhauled the funding rules to allow fees from big pharma to cover overhead as government funding dries up. Successor to founder Raymond Woosley, who retired last year, Compton shares her vision for securing the institute’s finances for the future amid tough economic times.
You may also be interested in...
Europe To Drive Global R&D Collaborations With Pharma Companies
Alzheimer’s disease research could be a beneficiary of Europe’s plan to include more non-EU partners in its new science funding program, Horizon 2020, and a new version of its public-private partnership with the pharmaceutical industry, the Innovative Medicines Initiative.
FDA’s Data Format Standards Approaching Cost-Benefit Analysis Stage
The agency sets a meeting for November and wants comments in advance on potential candidates for a format that will reduce the need for data integration steps between its various systems.
Critical Path Institute Seeks "Respected, Well Networked" CEO As Woosley Plans Retirement
Board member Bob Assenzo will lead a search committee to find a replacement for CPI's founding force, Raymond Woosley, who will step down next January.